Biotechnology Cancer Cures Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (197)	11/8/2000 12:41:56 PM
From: Jim Oravetz	Read Replies (1) of 226

SuperGen Says Decitabine May Play Significant Cancer Role Dow Jones Newswires SAN RAMON, Calif. -- SuperGen Inc. (SUPG) said data from several studies show that its decitabine may play a "significant role" in the future therapy of hematologic and solid cancers. The data was presented at Mount Sinai School of Medicine's XVIII Chemotherapy Foundation Symposium. In a press release Wednesday, SuperGen said three studies of decitabine to treat myelodysplastic syndrome in 125 patients showed an overall response rate of 49%. An additional study using decitabine to treat chronic myelogenous leukemia in 81 patients had a 62% response rate among patients in chronic phase of the disease. On Nov. 2, the company said decitabine generated a response in 100% of the patients tested in a Phase I/II clinical study designed to establish safety and efficacy in the treatment of sickle cell anemia Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next